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THE DOCTOR, THE PATIENT, AND EU LAW: THE IMPACT OF FREE 
MOVEMENT LAW ON QUALITY STANDARDS IN THE HEALTHCARE SECTOR 
Barend van Leeuwen*  
University of Groningen  
Abstract 
This article analyses the impact of the free movement provisions on quality of healthcare in the 
EU.  The application of the free movement provisions in the healthcare sector has restricted the 
freedom of Member States to set their own medical standards. International scientific evidence 
has to be taken into account. This impact reaches beyond the provision of cross-border 
healthcare. As a result, patients who are unable to travel abroad also benefit from higher medical 
standards. Individual challenges to national legislation under the free movement provisions are 
more successful in improving medical standards than adopting uniform European standards. 
Without a genuine internal market for healthcare services, European minimum standards do not 
contribute to improving the quality of healthcare in the EU. 
Introduction 
The judgments of the Court of Justice of the European Union (“the Court”) in Decker1 and Kohl2 
gave a very clear message to the Member States: although the EU does not have the competence 
to tell Member States how they should organise their healthcare systems,3 this does not mean that 
the Court cannot review whether the way in which Member States have organised their 
healthcare systems is compatible with EU law. As a result, Member States have to comply with 
                                                          
* Assistant Professor of European Law, University of Groningen, The Netherlands. I am grateful to Carla Sieburgh 
and Jan Zglinski for their comments.  
1 Decker v Caisse de maladie des employés privés (C-120/95) [1998] E.C.R. I-1831.    
2 Kohll v Union des caisses de maladie (C-158/96) [1984] E.C.R. 3651. 
3 Article 168(7) TFEU now provides that “Union action shall respect the responsibilities of the Member States for 
the definition of their health policy and for the delivery of health services and medical care. The responsibilities of 
the Member States shall include the management of health services and medical care and the allocation of resources 
assigned to them”. 
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the free movement provisions in the organisation of their healthcare systems. The judgments in 
Decker and Kohl were followed by a series of cases on the rights of patients to freely receive 
healthcare services in another Member State.4 This series of cases resulted in the adoption of 
Directive 2011/24/EU on the application of patients’ rights in cross-border healthcare (“the 
Cross-Border Healthcare Directive”).5 The main aim of the Directive was to codify the case-law 
of the Court and to add a number of provisions on administrative cooperation between public 
authorities in the Member States. The impact of the Court’s case-law and the Cross-Border 
Healthcare Directive on national healthcare systems has been analysed extensively in the 
literature.6  
This article will focus on the impact of free movement law on the quality of healthcare that 
patients are entitled to receive under national healthcare systems. There are significant differences 
in the quality of healthcare that is provided in the Member States.7 The financial crisis has put 
pressure on Member States to reduce costs and to cut budgets. This could lead to a reduction of 
the kind of medical treatments and the quality of healthcare.8 The application of the free 
movement provisions to other social areas of law, such as employment law, has been criticised 
                                                          
4 The most important cases were Vanbraekel and others v Alliance nationale des mutualités chrétiennes (C-368/98) [2001] 
E.C.R. I-5363; Geraets-Smits v Stichting Ziekenfonds and Peerbooms v Stichting CZ Groep Zorgverzekeringen (C-157/99) [2001] 
E.C.R. I-5473; Müller-Fauré v Onderlinge Waarborgmaatschappij ZAO Zorgverzekeringen and van Riet v Onderlinge 
Waarborgmaatschappij ZAO Zorgverzekeringen (C-385/99) [2003] E.C.R. I-4509; Inizan v Caisse primaire d’assurance maladie 
des Hauts-de-Seine (C-56/01) [2003] E.C.R. I-12403 and The Queen ex parte Watts v Bedford Primary Care Trust and Secretary 
of State for Health (C-372/04) [2006] E.C.R. I-4325. 
5 Directive 2011/24/EU of the European Parliament and of the Council on the application of patients’ rights in 
cross-border healthcare. 
6 See, inter alia, J. Bacquero Cruz, “The Case Law of the European Court of Justice on the Mobility of Patients” in F. 
Benyon (ed.), Services and the EU Citizen (Oxford: Hart Publishing, 2013), p. 87; in the same volume: R. Cisotta, 
“Limits to the Rights to Health Care and the Extent of Member States’ Discretion to Decide on the Parameters of 
Their Public Health Policies”, p. 113; A. Dawes, “ “Bonjour Herr Doctor”: National Healthcare Systems, the 
Internal Market and Cross-Border Medical Care within the European Union” (2006) 33 Legal Issues of Economic 
Integration 167; V. Hatzopoulos, “Killing National Health and Insurance Systems but Healing Patients? The 
European Market for Health Care Services after the Judgments of the ECJ in Vanbraekel and Peerbooms” (2002) 39 
C.M.L. Rev. 683; W. Palm and I. Glinos, “Ensuring Patient Mobility in the EU: Between Free Movement and 
Coordination” in E. Mossialos et al. (eds), Health Systems Governance in the EU: The Role of EU Law and Policy 
(Cambridge: CUP, 2010), p. 509. 
7 H. Legigo-Quigley et al., “Quality and safety” in M. Wismar et al., Cross-border Health Care in the European Union 
(Copenhagen: EOHSP, 2011), p. 121. 
8 M. Karanikolos et al., “Financial crisis, austerity and health in Europe” (2013) 381 Lancet 1323; M. Frischhut and 
R. Levaggi, “Patient mobility in the context of austerity and an enlarged EU: The European Court of Justice’s ruling 
in the Petru case” (2015) 119 Health Policy 1293. 
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for leading to lower standards of protection and a race to the bottom,9  and similar criticism has 
been made about their impact on the healthcare sector.10 However, the application of the free 
movement provisions to the healthcare sector has the potential to improve quality of healthcare 
in the EU. This potential reaches beyond the provision of cross-border healthcare – i.e. to 
patients who travel to another Member State for  medical treatment – and also has an impact on 
patients who remain in their home Member State.11  The free movement provisions require 
Member States to assess the quality of healthcare that patients are entitled to receive in their 
home Member State and to compare this with the quality of healthcare provided in other 
Member States. International scientific evidence and international medical standards have to be 
taken into account. Article 4(1)(b) of the Cross-Border Healthcare Directive provides that 
medical treatment shall be provided in accordance with the standards laid down by the Member 
State of treatment. However, recent case law of the Court of Justice of the European Union (“the 
Court”) shows that the comparative assessment required by the free movement provisions can 
force Member States to make available healthcare which would not have been made available to 
patients if the free movement provisions had not been applied. This impact is particularly visible 
in Member States that do not have many medical standards in place, or in Member States where 
the quality of healthcare is relatively low in comparison with other Member States.  
The impact of free movement law on healthcare standards will be analysed by focussing on three 
“layers” of EU regulation. First of all, we will look at the impact of Article 56 TFEU. The main 
impact of Art. 56 TFEU has been to harmonise the procedural standards with which Member 
States have to comply in deciding whether a patient should be authorised to receive medical 
treatment in another Member State. However, through the inclusion of certain procedural 
conditions, the Court has already started to encourage a process of Europeanisation of the 
                                                          
9 S. Deakin, “Regulatory Competition after Laval” (2008) 10 Cambridge Yearbook of European Legal Studies 581. 
10 C. Newdick, “Citizenship, Free Movement and Health Care: Cementing Individual Rights by Corroding Social 
Solidarity” (2006) 43 C.M.L. Rev. 1645; M. Ferrera, “Beyond National Social Rights?” in N. McEwen and L. Moreno 
(eds.), The Territorial Politics of Welfare (London: Routledge, 2005), p. 225.  
11 See also M. Flear, “Developing Euro-Biocitizens Through Migration for Healthcare Services” (2007) 14 Maastricht 
J. Eur. & Comp. L. 239. 
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medical standards that regulate quality of healthcare at the national level. Secondly, the Cross-
Border Healthcare Directive has gone one step further and has positively harmonised the 
information requirements that a doctor has to comply with to guarantee that a patient is able to 
provide informed consent to treatment.12 Although these standards have been harmonised in the 
context of cross-border healthcare, it is unlikely that Member States will make a distinction 
between treatment to national and non-national patients. Furthermore, the Cross-Border 
Healthcare Directive has introduced the concept of good quality healthcare.13 While this concept 
has not expressly found its way into the case-law of the Court yet, it limits the freedom of 
Member States to determine the quality of healthcare they provide to their citizens. Finally, the 
article will analyse self-regulation at the European level by looking at European standardisation in 
the healthcare sector. In a number of healthcare sectors attempts have been made to agree on 
European standards through European standardisation. It is clear that it is much more difficult to 
agree on a set of European standards than to challenge national legislation under the free 
movement provisions. Moreover, the adoption of European standards in the healthcare sector 
could actually lead to lower medical standards throughout the EU. The differences in quality 
standards serve as a catalyst in encouraging Member States to adopt higher quality standards. 
Through their reliance on free movement law, patients from Member States with lower medical 
standards “bring home” higher quality standards and new medical treatments. Member States 
have to take these standards into account also at the national level. Such a strategy to improve 
quality standards in the healthcare sector would be more successful than aiming to adopt one 
uniform set of European healthcare standards. 
The right to freely receive services in Article 56 TFEU 
The general principles and the impact on procedural standards 
                                                          
12 Article 4(2)(b) of the Cross-Border Healthcare Directive. 
13 Article 4(1) of the Cross-Border Healthcare Directive. 
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The key outcome of the Court’s judgments in Kohl and Decker was that the right of patients to 
receive healthcare services in another Member State was included in the scope of application of 
Article 56 TFEU. The general rule developed by the Court was that Member States were obliged 
to reimburse the costs of medical treatment in another Member State at the same rate they would 
have paid if treatment had taken place in the home Member State. If the treatment in the other 
Member State was more expensive, the patient would only receive the amount of compensation 
he would have received in the home Member State.14 Moreover, for medical treatment that 
required hospitalisation in the Member State of treatment, the home Member State was allowed 
to require a patient to obtain prior authorisation before going abroad for treatment. The 
subsequent cases before the Court focussed mainly on the procedural requirements that Member 
States had to comply with in deciding whether to grant prior authorisation for treatment in 
another Member State. Member States have to have transparent procedures in place, and 
decisions have to be taken within a reasonable period of time. They have to be open to judicial or 
quasi-judicial review.15 It is no longer possible for Member States to refer to the acceptable length 
of national waiting lists as a reason to refuse authorisation. Each case has to be assessed 
individually and the individual circumstances of a patient should properly be taken into account.16 
This has effectively imposed an obligation on Member States to introduce flexibility in their 
waiting lists.17 Finally, because Member States are obliged to reimburse the costs of treatment 
abroad up to the level of compensation a patient would have received in the home Member State, 
Member States have had to improve the transparency of the costs of medical treatment.18 In 
Member States with a healthcare system based on benefits in kind, such as the United Kingdom, 
                                                          
14 Conversely, if the treatment in the other Member States was cheaper than the treatment in the home Member 
State, the patient can still be compensated up to the level he would have received in the home Member State: 
Vanbraekel (C-368/98). 
15 Geraets-Smits (C-157/99) at [90]. 
16 Watts (C-372/04) at [119-120]. 
17 See J. Montgomery, “Impact of European Union Law on English Healthcare Law” in M. Dougan and E. Spaventa 
(eds), Social Welfare and EU Law (Oxford: Hart Publishing, 2005), p. 154. 
18 J. Montgomery, “Impact of European Union Law on English Healthcare Law” in M. Dougan and E. Spaventa 
(eds), Social Welfare and EU Law (Oxford: Hart Publishing, 2005), p. 154-155. 
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the costs of treatments have to be made accessible to patients – even if they would not normally 
see the price of these treatments because they do not have to pay for them.19 
Overall, the Court’s case-law has resulted in the creation of a set of European standards Member 
States have to comply with in the process of reimbursing or authorising medical treatment in 
another Member State. These procedural standards do not have an impact on the medical 
standards that are applicable to the medical treatment in another Member State. The possibility of 
free movement of patients could encourage Member States to exchange national standards – as 
we shall see later, this is something which is expressly confirmed by the Cross-Border Healthcare 
Directive –20, but it does not require them to move from national standards to European 
standards.    
Towards an impact on medical standards: Smits-Geraets and Peerbooms 
Despite the fact that the main impact of the case-law under Article 56 TFEU has been on 
procedural standards, the procedural standards imposed by the Court have also had a spill-over 
effect on standards that directly regulate medical treatment. This is clear from the Court’s 
judgment in Smits-Geraets and Peerbooms. Mrs Smits-Geraets was a Dutch national who had 
Parkinson’s disease. She wanted to go to a specialised centre in Germany for multidisciplinary 
treatment that she claimed was not available in the Netherlands. Mr Peerbooms fell into a coma 
after a road accident. After a while he was transferred to a hospital in Innsbruck (Austria) to 
receive experimental neuro-stimulation treatment that was not available in the Netherlands. In 
both cases the Dutch health insurer refused to provide authorisation for treatment in another 
Member State. In Mr Peerbooms’ case this meant that his treatment in Austria would not be 
reimbursed by the health insurer. For Mrs Smits-Geraets, this decision was taken primarily on the 
ground that adequate treatment was available in the Netherlands and that there was no medical 
                                                          
19 E. Zanon, “Implications of the EU Directive on cross-border health care for the English NHS” (2011) 17 
Eurohealth 34. 
20 Article 10 of the Cross-Border Healthcare Directive. 
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necessity for her to obtain treatment in another Member State. In the case of Mr Peerbooms, the 
refusal to provide reimbursement was based on scientific uncertainty about the effectiveness of 
neuro-stimulation. Furthermore, it was argued that adequate treatment was available in the 
Netherlands. 
The Court used the case to provide further guidance on the criteria that Member States were 
entitled to use in procedures for requests for prior authorisation. The decision of the Dutch 
health insurers to refuse authorisation – or, in Mr Peerbooms’ case, reimbursement – of 
treatment in another Member State constituted a restriction of the patients’ right to freely receive 
healthcare services in another Member State.21 This refusal could be justified by the aim to 
guarantee that patients had “sufficient and permanent access to a balanced range of high-quality 
hospital treatment in the State concerned”.22 However, the Court then specifically analysed the 
conditions applied by the health insurers. It focussed on two conditions: firstly, that the 
treatment for which prior authorisation was requested had to be “normal in the professional 
circles concerned”; secondly, that the medical treatment was “necessary” – in other words, that 
there was a medical necessity to be treated in another Member State. As to the necessity 
requirement, the Court held that Member States could refuse prior authorisation of treatment if 
they could show that the same or equally effective treatment could be obtained without undue 
delay in the home Member State.23 This required a comparison between the potential treatment in 
the home Member State and the treatment abroad. As to the requirement that the treatment in 
the other Member State had to be “normal”, the Court held that “to allow only treatment 
habitually carried out on national territory and scientific views prevailing in national medical 
circles to determine what is or is not normal will not offer those guarantees and will make it likely 
that Netherlands providers of treatment will always be preferred in practice”.24 Therefore, Dutch 
                                                          
21 Geraets-Smits (C-157/99) at [69]. 
22 Geraets-Smits (C-157/99) at [72-75].  
23 Geraets-Smits (C-157/99) at [103]. 
24 Geraets-Smits (C-157/99) at [96]. 
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health insurers were required to take into account international scientific evidence – the question 
was whether the requested treatment had been “sufficiently tried and tested by international 
medical science”.25  
The requirement that Member States consider international medical science in deciding whether 
treatment is normal means that Member States cannot rely exclusively on national standards. The 
Court has imposed an obligation on Member States to analyse international scientific evidence 
that is available in a particular field of medicine. Member States have to assess to what extent 
their national healthcare system is able to provide healthcare services in accordance with that 
international scientific evidence. From this perspective, it can no longer be maintained that 
Member States can assess requests for prior authorisation exclusively from the perspective of 
national standards of treatment. It is important to emphasise the link between international 
scientific evidence and medical standards. Most standards in the healthcare sector are evidence-
based, which means that they are directly based on (international) scientific research.26 Research 
in medicine has to an important extent been internationalised – many of the standards used in the 
EU are based on research which has been undertaken in the US.27 While Member States retain 
discretion in deciding how international scientific evidence should be interpreted and how it 
should be “translated” to national medical practice,28 the fact remains that they can no longer 
close their eyes to what is happening in international medical science and to standards that have 
been adopted on the basis of international medical science.  
In Smits-Geraets and Peerbooms the Court made a direct link between free movement law and 
evidence-based medicine. Although Member States are only obliged to assess international 
                                                          
25 Geraets-Smits (C-157/99) at [94]. 
26 J. van Everdingen et al. (eds), Evidence-based richtlijnontwikkeling: een leidraad voor de praktijk (Houten: Bohn Stafleu, 
2004). See also E. Freidson, Profession of Medicine: A Study of the Sociology of Applied Knowledge (Chicago: UCP, 1988). 
27 N. Cortez, “International Health Care Convergence: The Benefits and Burdens of Market-Driven Standardization” 
(2008) 26 Wisconsin International Law Journal 646. 
28 A. Den Exter, “Health Care Access in the Netherlands: a True Story” in C. Flood and A. Gross (eds), The Right to 
Health at the Public/Private Divide (Cambridge: CUP, 2014), p. 200. See also G. Davies, “Legislating for Patients’ 
Rights” in J. van der Gronden et al. (ed.), Health Care and EU Law (The Hague: Asser, 2011), p. 204. 
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scientific evidence in the context of requests for authorisation to obtain treatment in another 
Member State, this obligation to go beyond national standards also has an  impact on medical 
treatment without a cross-border element. The obligation to refer to international medical science 
arose in the context of deciding what is “normal treatment”, which is a concept that is also 
relevant to medical treatment at the national level. This was already clear in Smits-Geraets and 
Peerbooms, because the Dutch health insurers were not allowed to discriminate between foreign 
healthcare providers and national healthcare providers with which they had not concluded 
contracts – which meant that patients could not go to these national providers without obtaining 
prior authorisation either.29 Through the obligation to assess international scientific evidence, the 
interpretation of what constitutes “normal” treatment at the national level is changed. Patients 
who have not travelled to another Member State for treatment also benefit from this.  
The Cross-Border Healthcare Directive 2011 
Harmonisation of information duties 
The main aim of the Cross-Border Healthcare Directive was to confirm and codify the case law 
of the Court and to clarify a number of concepts which had been developed in the case-law.30  
The Directive establishes a right for patients to receive treatment in another Member State and to 
be reimbursed for this treatment up to the level of costs patients would have received if they had 
stayed in their home Member State.31 It also provides a clearer definition of hospitalisation, which 
is now restricted to treatment for which a patient has to spend a night in hospital.32 Therefore, 
Member States are no longer entitled to impose a system of prior authorisation for out-patient 
treatment in a hospital in another Member State which is provided on the same day. Article 
4(1)(b) provides that cross-border healthcare shall be provided in accordance with “standards and 
                                                          
29 Geraets-Smits (C-157/99) at [93]. 
30 For a detailed discussion, see S. De La Rosa, “The Directive on Cross-Border Healthcare or the Art of Codifying 
Complex Case Law” (2012) 49 C.M.L. Rev .15. See also W. Sauter, “Harmonisation in healthcare: the EU patients’ 
rights Directive” (2011) TILEC Research Paper 6. 
31 Article 7 of the Cross-Border Healthcare Directive. 
32 Article 8(2)(a)(i) of the Cross-Border Healthcare Directive. 
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guidelines on quality and safety laid down by the Member State of treatment”. As such, the 
Member State of treatment determines the quality of healthcare to which patients are entitled. 
However, while the Directive does not impose a certain level of healthcare on the Member 
States, it places an obligation on them to have standards in place. In order to be able to provide 
information about the applicable medical standards, which is required under Article 4(2)(a), 
Member States have to be able to provide information about the applicable medical standards in 
their territory. If Member States do not have such medical standards in place, they would not be 
able to fulfil their obligations under the Directive. As a result, the implementation of the 
Directive has resulted in a more proactive attitude by a number of Member States in adopting – 
or encouraging the adoption of – medical standards. This can be observed in some of the newer 
Member States and in some older Member States.33 If there are no national standards, Member 
States may decide to rely on international or European standards.34 As a result, the application of 
free movement law again stimulates a process of internationalisation or Europeanisation of 
medical standards. Moreover, in some Member States that already have plenty of medical 
standards, the Directive has encouraged the Member States to be more transparent about the 
applicable medical standards.35  
One of the main novelties of the Cross-Border Healthcare Directive is that it also imposes a 
number of information duties on healthcare providers. In doing so, the Directive aims to give 
patients a number of consumer-like rights which are necessary to ensure that they are able to 
provide informed consent to treatment.36 Article 4(2)(b) of the Directive imposes a number of 
obligations on healthcare providers. They have to provide information about the treatment 
                                                          
33 S. Olsena, “Implementation of the Patients’ Rights in Cross-Border Healthcare Directive in Latvia” (2014) 21 
European Journal of Health Law 46, 51; M. Schwebag, “Implementation of the Cross-border Care Directive in EU 
Member States: Luxembourg” (2014) 21 European Journal of Health Law 56, 64. 
34 M. Schwebag, “Implementation of the Cross-border Care Directive in EU Member States: Luxembourg” (2014) 
21 European Journal of Health Law 56, 62. 
35 L. Bongers and D. Townend, “The Implementation of the Directive on the Application of Patients’ Rights in 
Cross-border Healthcare in the Netherlands” (2014) 21 European Journal of Health Law 65, 73. 
36 This was the approach argued for by G. Davies, “The Community’s Internal Market-Based Competence to 
Regulate Healthcare: Scope, Strategies and Competences” (2007) 14 Maastricht J. Eur. & Comp. L. 215. 
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options, about the availability of healthcare, about the quality and safety of healthcare and about 
the prices and invoices for the treatment. By granting these information rights to patients the 
Directive enters directly “into the treatment room” and requires Member States to guarantee that 
doctors provide a certain amount of information to patients. This constitutes harmonisation of 
the information duties imposed on healthcare providers. In principle, it is limited to information 
provided to patients in the context of cross-border healthcare. The various information duties 
mentioned in Article 4(2)(b) only apply to healthcare that is provided to patients from another 
Member State. However, in fact, it is unlikely that Member States will create separate information 
duties for national patients and patients from other Member States.37 The only element where a 
distinction could be made is with respect to the language in which the information is provided.  
The final part of the Cross-Border Healthcare Directive which should be discussed is Chapter IV 
on cooperation in healthcare. This Chapter encourages Member States to exchange information. 
Article 10 on mutual assistance and cooperation provides that “Member States shall render such 
mutual assistance as is necessary for the implementation of this Directive, including cooperation 
on standards and guidelines on quality and safety and the exchange of information”.38 Such an 
exchange of information between Member States could lead to the realisation that it might be 
more convenient to adopt European standards in a particular field or sector. However, the 
Directive does not go beyond the mere exchange of national standards and guidelines – there is 
no direct encouragement of the adoption of European standards.  
The concept of good quality healthcare: the impact of Elchinov and Petru 
Similarly to the potential impact of the case-law under Article 56 TFEU through the 
interpretation of the concept of “normal treatment” in Smits-Peerbooms, the Cross-Border 
Healthcare Directive could have a more indirect impact on the freedom of Member States to 
                                                          
37 D. Delnoij and W. Sauter, “Patient information under the EU’s patients’ rights Directive” (2011) 21 European 
Journal of Public Health 271. 
38 Article 10(1) of the Cross-Border Healthcare Directive 
12 
 
determine their own quality standards in the healthcare sector. Article 4(1) states that in providing 
cross-border healthcare Member States shall take into account the principle of “good quality 
care”. The Directive also refers a number of times to the concept of “a balanced range of high-
quality treatment in the Member State concerned”.39 The two concepts are not expressly defined 
in the Directive – it is not indicated what level of healthcare should be provided in order to 
comply with the principle of good quality healthcare. It could be argued that, because there is no 
express reference to national standards, the two concepts are autonomous EU law concepts that 
are not affected by the Member States’ interpretation of good quality or high-quality care. 
However, because the whole Directive is expressly based on the idea that medical treatment shall 
be provided in accordance with national quality standards laid down by the Member State of 
treatment, it is difficult to argue that the concepts of good quality and high-quality care should be 
given an autonomous European interpretation. Nevertheless, it is clear that these references are 
strongly influenced by the aim to protect fundamental rights. Article 35 of the Charter of 
Fundamental Rights (“the Charter”) protects the right of patients to have access to preventive 
healthcare. In combination with the concept of good quality care, it could have an impact on the 
interpretation of the Cross-Border Healthcare Directive.40 This will be illustrated by an analysis of 
the Court’s judgments in Elchinov41 and Petru.42 
Mr Elchinov was a Bulgarian national who was covered by the Bulgarian health insurance system. 
He had a tumour in his eye and the only treatment that was available in Bulgaria was the 
complete removal of the eyeball. More advanced treatment, that would not require the complete 
removal of the eyeball, was available in Germany. Therefore, Mr Elchinov applied for prior 
authorisation to be treated in a specialist clinic in Berlin. Because of the urgency of the situation 
he did not wait to hear the result of his application. The relevant Bulgarian legislation provided 
                                                          
39 Article 1(1), Article 4(3), Article 7(7), Article 7(9) and Article 8(2)(a) of the Cross-Border Healthcare Directive. 
40 See also T. Hervey and J. McHale, European Union Health Law (Cambridge: CUP, 2015), p. 163-165. 
41 Elchinov v Natsionalna zdravnoosiguritelna kasa (C-173/09) [2010] E.C.R. I-8889. 
42 Petru v Casa Judeteana de Asigurari de Sanatate Sibiu (C-268/13) ECLI:EU:C:2014:2271. 
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that patients covered by the Bulgarian health insurance were entitled to “other operations on the 
eyeball” and to “high-technology radiotherapy for oncological and non-oncological conditions”.43 
The Bulgarian authorities held that this did not include the highly specialised treatment that Mr 
Elchinov received in Berlin and refused to provide authorisation. This was because the treatment 
was not available in Bulgaria. As a result, Mr Elchinov, who had already received the treatment in 
Berlin, had to pay the costs of the treatment himself. He appealed against the refusal of the 
Bulgarian authorities to reimburse his treatment. Before the Bulgarian court, it was confirmed by 
an expert that the treatment Mr Elchinov had received in Germany was not available in 
Bulgaria.44 
The Court had to decide if medical treatment that was not available in Bulgaria could still be held 
to be covered by the Bulgarian health insurance system. The Bulgarian legislation referred to 
“other operations on the eyeball”, which was a relatively open category that had been interpreted 
restrictively by the Bulgarian authorities. The question was if this restrictive interpretation 
breached Mr Elchinov’s right to freely receive services under Article 56 TFEU. The Court held 
that national authorities could not presume that “hospital treatment which cannot be given in the 
Member State on whose territory the insured person resides is not included in the benefits for 
which reimbursement is provided for by the legislation of that State or, conversely, that the 
hospital treatment included in those benefits can be given in that Member State”.45 As a result, 
the Bulgarian authorities could not simply presume that because the specialist treatment available 
in Germany could not be offered in Bulgaria, it was not covered by the Bulgarian health 
insurance system. As a result, the Court has effectively imposed a duty of consistent 
interpretation on national courts. However, it is a special kind of consistent interpretation, which 
is based on the vagueness of provisions of national law. If it is at all possible to bring a foreign 
treatment within the category of treatments that are reimbursed by the home Member State, the 
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44 Elchinov (C-173/09) at [18]. 
45 Elchinov (C-173/09) at [73]. 
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national court should do so. This kind of duty of consistent interpretation is different from the 
traditional doctrine of consistent interpretation in the field of directives, where there are clear EU 
law rights that have to be accommodated in national law by relying on the potential openness or 
vagueness of national law. The duty of consistent interpretation developed in Elchinov works the 
other way around – it starts with the vagueness of national law, which subsequently creates an 
obligation to interpret it in the most “free-movement-friendly” way. This duty could also have an 
impact on the availability of the treatment at the national level – if a treatment is found to be 
covered by the home Member State, this also encourages healthcare providers to provide the 
treatment to patients who are not receiving cross-border healthcare. 
In Elchinov, Bulgaria was in a way punished for using the relatively open category of “other 
operations on the eyeball” in the relevant Bulgarian legislation. The open character of the 
category enabled the Court to hold that in such cases the national authorities ruling on requests 
for prior authorisation should find that a specialist treatment was included in the treatments 
covered by the home Member State. This could result in Member States defining the categories 
of treatments that are covered by the home Member State in a much more restrictive way, with 
the result that they leave no doubt as to the treatments that are covered.46 A duty of consistent 
interpretation would then not be possible, because it cannot be used in cases where the national 
legislation provides that a particular kind of medical treatment is not covered. Such a restrictive 
policy could potentially be in breach of the Cross-Border Healthcare Directive or Article 56 
TFEU.47 Elchinov could be used to argue that the concept of good quality healthcare prevents 
Member States from going below a certain level of quality and that certain medical treatments 
have to be covered by the home Member State’s insurance system. This would also have an 
important impact on the medical standards that would be applicable to these treatments. Again, 
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Member States would have to provide healthcare of a higher quality at the national level. The 
freedom of Member States to determine what kind of quality of healthcare is offered to patients 
is restricted. This can be seen in Petru. Ms Petru was waiting for complicated open heart surgery 
in a Romanian hospital, when she discovered that the hospital did not have some basic medical 
equipment and facilities. Therefore, she decided to travel to Germany for treatment. She later 
claimed reimbursement from her Romanian health insurer. Reimbursement was denied on the 
basis that the treatment was available within a reasonable period of time in Romania. The Court 
had to decide whether authorisation could be refused when a hospital did not have sufficient 
resources to offer a particular kind of treatment. It concluded that authorisation cannot be 
refused “where it is because of a lack of medication and basic medical supplies and infrastructure 
that the hospital care concerned cannot be provided in good time in the insured person’s 
Member State of residence”.48 
Petru clarifies that a lack of resources in hospitals in the patient’s home Member State constitutes 
a valid reason to travel abroad for treatment in another Member State. However, the main focus 
of the judgment is not on the cross-border aspect, but on the obligation that is imposed on the 
home Member State. The Court imposed an obligation on the Romanian court to assess whether 
the treatment she required could be provided in another hospital in Romania. This is not 
dissimilar to the duty of consistent interpretation imposed on national courts in Elchinov – the 
national court is required to do all it can to guarantee that a patient can receive adequate medical 
treatment in the home Member State. The effect of this obligation is that the Romanian health 
insurer has to do its best to ensure that Ms Petru could receive adequate treatment in a Romanian 
hospital without having to travel to another country. If the required quality of care cannot be 
provided in the hospital where Ms Petru was being treated, it would be necessary to look for 
other hospitals in Romania where the required quality of care could be provided. Cross-border 
healthcare only becomes legitimate when all options in the home Member State have been 
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assessed and have been found inadequate. As such, the application of free movement law again 
has an impact on the quality of healthcare that is provided in the home Member State. In future 
cases similar to Petru, an assessment will have to be made to determine whether adequate 
treatment can be provided in Romania. The potential “threat” of free movement of patients 
forces Member States to provide healthcare of a higher quality in their territory. As a 
consequence, it is no longer necessary for patients to travel across borders for treatment and that 
medical treatment of a higher quality will be offered in their home Member State.    
European standardisation in the healthcare sector 
The role of European standardisation in the healthcare sector 
It is clear that Article 56 TFEU and the Cross-Border Healthcare Directive have an indirect 
impact on the freedom of Member States to determine the applicable quality standards for 
medical treatment. They limit the discretion of Member States to decide on the applicable 
medical standards. However, with the exception of the information duties in Article 4(2) of the 
Cross-Border Healthcare Directive, there has not been any harmonisation of medical standards at 
the European level. In theory, such harmonisation could be realised by relying on the EU’s 
competence under Article 114 TFEU to improve the functioning of the internal market.49 
Differences in medical standards could make it less attractive for patients to travel to another 
Member State for treatment. However, it would first have to be shown that there is in fact an 
internal market for healthcare services and that the adoption of European standards would 
improve this internal market.50 Furthermore, it is unrealistic to assume that Member States would 
be willing to accept European standards in the healthcare sector, since healthcare is a field in 
which Member States are particularly protective of their national sovereignty. The fact that 
                                                          
49 For a detailed discussion, see D. Wyatt, “Community Competence to Regulate Medical Services” in M. Dougan 
and E. Spaventa (eds), Social Welfare and EU Law (Oxford: Hart Publishing, 2005), p. 131. 
50 The number of patients travelling to another Member State for medical treatment remains low. See European 
Commission, ‘Commission Report on the operation of Directive 2011/24/EU on the application of patients’ rights 
in cross-border healthcare’ COM(2015) 241 final.  
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harmonisation of medical standards is unlikely does not mean that there are no alternative ways 
to adopt European standards in the healthcare sector.51 “Softer” alternatives such as self-
regulation or co-regulation could be possible.52 At the European level, this opens up the 
possibility of European standardisation of healthcare services. 
European standardisation is a process of self-regulation at the European level. It has become 
prominent through product standardisation.53 All Member States have their own national 
standardisation organisations, while the European standardisation organisation CEN is based in 
Brussels. If a European standard is made for a particular product, a so-called “technical 
committee” meets at CEN in Brussels to decide on the technical standards this product should 
comply with. The technical committee consists of representatives of national “mirror 
committees” that meet at the national standardisation organisations and that closely follow the 
European standardisation process. European standardisation is open to all stakeholders who are 
willing and able to participate – the result is that European standards can be made by businesses, 
consumer organisations, business associations and even by public authorities. All these parties 
meet in Brussels to agree on a set of European standards for a particular product. Once such a 
European standard has been adopted, it remains a self-regulatory instrument with no binding 
force in law per se.54 However, Member States could decide to refer to such standards in 
legislation, in which case European standards would be applied in public law. Similarly, 
stakeholders in particular sector could apply standards in contracts – they could include a term in 
the contract that a particular product has to comply with a European standard – or in 
certification schemes. As such, European standards can also be applied in private law. Because it 
proved difficult to harmonise European product standards through the legislative process, the 
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EU decided to incorporate European standardisation in a new regulatory approach to goods – 
the “New Approach”.55 The basic idea behind the New Approach is relatively simple – the EU 
adopts general product safety directives which lay down the “essential requirements” with which 
products have to comply. The precise technical specifications are laid down in European 
standards developed through European standardisation. Once the reference of a European 
standard has been published in the OJEU, it is presumed that products that comply with the 
European standard also fulfil the essential requirements of the relevant directive. Although 
manufacturers are free to try and show by other means that they comply with the directive, in 
fact most of them choose to comply with the European standard. Therefore, European 
standardisation has obtained a prominent role in the EU’s internal market for goods. 
No such New Approach has been developed in the field of services. There are no European 
directives on the safety of services which are supplemented by European services standards. 
Although there is a reference to European standardisation of services as a tool to improve the 
quality of services in the Services Directive 2006,56 this remains an isolated reference which is not 
embedded in a broader regulatory approach to services.57 Nevertheless, in the last decade or so, a 
significant number of European services standards has been adopted through European 
standardisation.58 European standardisation of services is a new regulatory tool in the services 
sector, which has been enthusiastically supported by CEN. European services standards define 
the level of quality service recipients are entitled to expect before, during and after the service 
process. It is not immediately clear what role these standards are supposed to play in the legal 
regulation of services. A second step is necessary to provide binding effect to European services 
                                                          
55 Council Resolution of 7 May 1985 on a new approach to technical harmonization and standards (85/C 136/01). 
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56 Article 26(5) of the Services Directive. 
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standards in law. The healthcare sector is one of the sectors in which a number of European 
services standards has been made. Some European standardisation processes provoked very 
strong reactions by doctors, patients and public authorities. European standards in the healthcare 
sector interact directly with free movement law – in particular, with Article 56 TFEU. This will be 
shown through an analysis of a recent example of European standardisation in the healthcare 
sector.  
A European standard for Cleft Lip Surgery Services 
In January 2011 the European Cleft Organisation (“ECO”), a European patient organisation for 
babies born with cleft lips, submitted a proposal for a European standard for Cleft Lip Surgery to 
the Bulgarian standardisation organisation.59 It had specifically chosen the Bulgarian 
standardisation organisation because it wanted to raise awareness in some of the new Member 
States. As a patient organisation, ECO’s main aim was to ensure that there were minimum 
standards for cleft lip treatment in all EU Member States. Although it accepted that the standards 
are widely divergent across the EU, it argued that all EU citizens should be entitled to treatment 
in accordance with certain minimum standards. It was particularly concerned about the medical 
standards in Bulgaria and Romania. As such, there is a clear link to Elchinov and Petru. The Cross-
Border Healthcare Directive is not of much use to patients with cleft lips, because babies born 
with cleft lips need a series of treatments during a number of years. Moreover, cross-border 
treatment is unrealistic because families of babies born with cleft lips in countries like Bulgaria or 
Romania do not usually have the financial resources to travel to another Member State for 
treatment. For those reasons, ECO wanted to develop a European standard that would empower 
patients and their families to demand a certain quality of care. Because a European 
standardisation process would potentially bring together various stakeholders from different 
Member States, ECO believed that European standardisation would be the best tool to adopt a 
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European standard for Cleft Lip Surgery. A European standard would not override national 
legislation, which meant that the significant differences in national legislation should not be 
problematic. 
After a proposal for a European standard has been submitted to one of the national 
standardisation organisations, all national standardisation organisations have to vote on whether 
they are in favour of the development of a European standard in that field. Two-thirds of the 
votes casted have to be in favour and there have to be at least five national standardisation 
organisations that are willing to actively contribute to the development of the standard.60 In 
practice, this means that national standardisation organisations have to consult relevant 
stakeholders to see if they are in favour of a European standard and if they are willing to 
participate in a European standardisation process. For the European standard for Cleft Lip 
Surgery, national standardisation organisations consulted stakeholders in early 2011. They voted 
on the proposal in April 2011.61 15 national standardisation organisations voted in favour of the 
creation of a European standard, while 5 voted against. There were 11 abstentions. As a result, 
the proposal was rejected. The national standardisation organisations of Finland, France, 
Germany, the Netherlands and Spain voted against. The opposition in France and Spain was 
particularly strong. The French explained their negative vote with the following comments: 
“Such a topic is considered as a very sensitive one linked to the patient safety. This is why in France the 
management of cleft lip and palate falls within the remit of the public authorities in charge of the health system, 
organised by dedicated regulations”62 
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The main objection of the French was that medical standards should be set by public authorities 
at the national level rather than through self-regulation at the European level. The comments of 
the Dutch standardisation organisation were different: 
“European standardization of healthcare services across Europe is unrealistic. Healthcare services for cleft lip and 
or palate in the Netherlands is aiming for optimal healthcare. Optimal healthcare might not be realistic 
(financially) for all individual countries. European standardization would most likely aim for an average level of 
healthcare. It is not in the interest of the Netherlands neither to develop nor to contribute to such a standard”63 
After the negative vote ECO organised a number of meetings in France and Spain to try and 
increase the support for a European standardisation process. However, it became clear that there 
was not enough support. ECO then considered the possibility of making of Workshop 
Agreement through CEN, which would be an instrument with a lower status than a European 
standard. Because some national standardisation organisations were also against the adoption of a 
Workshop Agreement, ECO decided to develop a Technical Report through CEN. A Technical 
Report did not have the same status as a European standard or a Workshop Agreement, but it 
still provided an opportunity to lay down a number of European standards for cleft lip surgery. 
The Technical Report was adopted in March 2015.64 
The case-study shows that European standardisation is one or two steps ahead of Article 56 
TFEU and the Cross-Border Healthcare Directive. With European standardisation medical 
standards are defined directly at the European level.  For the Cleft Lip Surgery standard, it was 
the inability of patients to exercise their free movement rights that encouraged ECO to take the 
initiative for one uniform European standard. Because of the limitations of the exercise of free 
movement rights, ECO wanted to raise the quality of healthcare at the national level in Bulgaria 
and Romania. It wanted to achieve this by adopting one uniform European standard that would 
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be applicable to all Member States. However, a significant number of the Member States were 
not willing to abandon their national standards in favour of a European standard. Two main 
objections can be observed. First, the regulatory competence of the Member States to determine 
the applicable medical standards was challenged much more directly by European standardisation 
than by the application of Article 56 TFEU and the Cross-Border Healthcare Directive. Under 
the free movement provisions, individual patients challenge the level of quality of healthcare that 
is provided in their home Member State by trying to benefit from treatment of a higher quality in 
another Member State. This process forces Member States to reconsider the quality of healthcare 
that is provided in their territory. The impact at the national level is indirect. With European 
standardisation, Member States have to accept that standards are set directly at the European 
level. Moreover, they are not set by the Member States themselves, but by private parties such as 
patient organisations.65 Quality of healthcare would be determined at the European level outside 
the direct control of the Member States. Although these European standards would not be 
binding in law, it is not surprising that Member States consider European standardisation as a 
threat to their regulatory competence.  
Second, European standardisation does not only have an impact on who determines the quality of 
healthcare patients are entitled to receive, but also on what level of quality patients are entitled to 
receive. European standardisation introduces one uniform standard. It aims to remove 
differences in quality of healthcare between the various Member States. This is an important 
difference with the impact of Article 56 TFEU and the Cross-Border Healthcare Directive.  The 
case law under Article 56 TFEU was primarily about patients who wanted to benefit from higher 
medical standards in another Member State. The basis of all cases was the existence of 
differences between the level of healthcare provided in the Member States. Changes in the quality 
of healthcare provided in the home Member State were required precisely because there were 
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(significant) differences. By imposing an obligation on Member States to assess international 
scientific evidence and to interpret national legislation consistently with this scientific evidence, 
Member States were put under pressure to increase medical standards at the national level. As a 
result, Member States were not required to lower medical standards.  
However, the picture is different for European standardisation. This leads to a development from 
negative integration to positive integration. Differences between medical standards in the various 
Member States are removed by adopting one uniform European standard. One of the basic 
principles of European standardisation outside the New Approach is that it only provides 
minimum standards. Member States remain free to use or to adopt standards that go beyond the 
minimum standards provided in European standards. This raises the question in what 
circumstances Member States would actually benefit from having European minimum standards 
in place. After all, if Member States already have higher national standards, why would it be 
necessary for them to agree on European minimum standards?  It is important to look at the 
reasons for adopting  European minimum standards. Because of the inherent characteristics of 
the treatment of patients with cleft lips, there is no internal market for cleft lip surgery. ECO 
wanted a European standard to remedy the limitations of the internal market. It wanted to 
increase the level of care for patients who were unable to move to another Member State for 
treatment. However, it is clear that, in the absence of an internal market, Member States with 
higher standards have no interest in adopting European minimum standards. This is clear from 
the Dutch explanation for their negative vote on the proposal.66 A European minimum standard 
would only result in pressure to lower current higher national standards. It would not be in the 
interest of these Member States to contribute to the adoption of European standards. European 
standardisation is rejected as a development aid tool to support some of the new Member States. 
These Member States regard European standardisation as initiating some sort of race to the 
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bottom, because they would have to agree on standards that are lower than their current medical 
standards. They are effectively saying that patients in countries with lower medical standards 
benefit more from the differences in standards – from certain Member States “setting the 
example” for other Member States – than from the adoption of one uniform European standard.  
The interaction between free movement law and quality of healthcare 
Harmonisation and standardisation in the healthcare sector: between positive and negative integration 
The analysis above has shown that the application of the free movement provisions has had an 
impact on the quality of healthcare that patients are entitled to receive under national healthcare 
systems. This impact is not limited to patients who have exercised their free movement rights, 
but also extends to the provision of healthcare at the national level. However, the impact has 
been indirect. The Court has been cautious not to interfere directly with the regulatory 
competence of the Member States to determine their medical standards. However, it has 
restricted the margin of discretion of Member States and it has forced them to review medical 
standards in light of international scientific evidence. In combination with the reference to the 
concept of “good quality care” in the Cross-Border Healthcare Directive, this means that clear 
boundaries have been set at the European level to the level of quality of healthcare that is 
provided to patients. In addition, the Court has imposed a duty of consistent interpretation, 
which means that national courts have to interpret national legislation in such a way that the 
highest quality of healthcare which can be provided within the limits of the national legislation is 
actually offered to patients. Overall, the result is that the application of free movement law has 
had a positive impact on the quality of healthcare patients are entitled to receive under national 
healthcare systems. 
The special characteristics of the healthcare sector have resulted in a rather different impact of 
the free movement provisions in comparison with other services sectors. Although the Court has 
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consistently held that Article 56 TFEU is applicable to healthcare services, the reality is that there 
is no real internal market for regular healthcare services.67 Patients rarely travel to another 
Member State for medical treatment.68 The cases that reached the Court primarily concerned 
wealthy citizens who had the financial means to profit from higher medical standards in other 
Member States, and who were subsequently able to reclaim the costs of medical treatment in 
their home Member States. Therefore, the main impact in the healthcare sector is more the result 
of the potential of free movement of patients than the actual cross-border movement of patients. 
Furthermore, it is not realistic to create one European level of quality of healthcare. Such a 
uniform level would not actually raise the overall quality of healthcare in the EU. Member States 
with higher medical standards are afraid that the removal of differences in quality would result in 
a lower overall level of quality of healthcare. The dynamics of the free movement provisions in 
the healthcare sector are special. Patients benefit most from trying to profit from differences in 
the quality of healthcare between Member States. As such, for free movement law to have a 
positive impact on the quality of healthcare, it is crucial that differences in national quality 
standards remain. The most effective strategy to improve medical standards at the national level 
is to use the free movement provisions as a tool to confront Member States with higher quality 
standards and to use free movement law to explore the potential of national legislation to apply 
these higher medical standards at the national level. This is the combined effect of Smits-Geraets, 
Elchinov and Petru.  
As a result, it would not actually be beneficial to attempt to harmonise or standardise quality of 
healthcare at the European level. The internal market for healthcare services is best served by 
maintaining differences between Member States. These differences encourage a race to the top 
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rather than a race to the bottom. European minimum standards would reduce differences and, as 
a consequence, would reduce the incentives for Member States to improve quality of healthcare. 
From a free movement perspective, this might be an unusual conclusion. For other sectors, the 
functioning of the internal market can best be guaranteed by having minimum standards of 
protection in place. Such minimum standards would not work in the healthcare sector. For the 
free movement provisions to be used as an effective tool to improve quality of healthcare, it is 
essential that differences in quality remain. The conclusion is that harmonisation and 
standardisation of medical standards at the European level should be resisted. The usual 
combination of positive and negative integration does not work in the healthcare sector. While 
positive integration by way of harmonisation would normally be the logical next step after 
negative integration through the removal of obstacles to free movement of services,69 the focus 
to improve quality of healthcare in the EU should solely be on negative integration.  
Individual rights as a catalyst for improving quality of healthcare 
Even without European harmonisation or standardisation in the healthcare sector, it is clear that 
Member States are no longer in exclusive control of the setting of medical standards. Private 
parties, such as associations of doctors or patient organisations, use the European perspective of 
the free movement provisions to try and force Member States to raise medical standards. The 
Cleft Lip Surgery example illustrates that patient organisations have tried to do this by 
campaigning for one European standard. This attempt failed because of resistance in some 
Member States with higher national standards. As a result, it would be more effective if patient 
organisations focussed on facilitating free movement of patients from Member States with a 
lower quality of healthcare to Member States with higher medical standards. For example, patient 
organisations could provide funding to patients to get medical treatment in another Member 
State. After the treatment, they could help them to obtain reimbursement from their home 
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Member State. Such a strategy would be more successful in raising the level of healthcare at the 
national level than to invest in the adoption of uniform European standards. Collective attempts 
to raise medical standards in certain Member States have the best chance of success if they 
collectively facilitate individual challenges to national medical standards. This might seem 
counterintuitive or even paradoxical, but it is not a new strategy at the European level.70 
The result is that through the exercise of their free movement rights patients “bring home” 
higher medical standards. The free movement provisions force Member States to take these 
standards into account. It is true that the motives of patients might have been egocentric. Mr 
Elchinov and Ms Petru were not aiming to raise the quality of care for all patients in Bulgaria and 
Romania – they just wanted to obtain the best possible treatment for themselves.  However, they 
still acted as “explorers” for other patients who were unable to rely on their free movement 
rights. It was only through the exercise of their free movement rights that they were able to force 
their national healthcare systems to take higher medical standards into account. It could be 
argued that most of these cases were about the availability of medical treatments, and not about 
the quality. However, there is close relationship between the availability of medical treatments, the 
quality of healthcare and medical standards. The treatments patients were seeking in these cases 
were not available in the home Member States, because they were based on medical standards 
that had not yet made their way into the national healthcare systems. The effect of the application 
of Article 56 TFEU was to encourage Member States to make these treatments available in the 
home Member State, in accordance with medical standards. Because most medical standards are 
based on scientific evidence, the availability of treatments of a higher quality necessarily means 
that higher medical standards will be applicable. 
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Finally, it remains problematic that Member States could potentially restrict the kind of medical 
treatments to which patients are entitled under the national healthcare system by creating more 
exhaustive and precise lists of medical treatments in national legislation. This remains the fear of 
patients in Member States where financial difficulties impose a big strain on healthcare budgets. 
However, it should be emphasised that such a rationing exercise would in itself be an expensive 
and time-consuming exercise for Member States. Cross-border movement of patients is not 
sufficiently common for it to be attractive for Member States to embark on such an exercise. 
Therefore, most Member States will continue to use relatively open-ended categories, which leave 
room for the incorporation of higher treatments and medical standards. If Member States really 
restricted healthcare to such an extent that certain essential medical treatments were no longer 
available, this would be the right occasion for the Court to give teeth to the concept of “good 
quality healthcare” in the Cross-Border Healthcare Directive. In combination with Article 35 of 
the Charter, this concept provides a powerful tool for the Court to argue that Member States 
cannot go below a certain minimum level of healthcare. 
Conclusion 
From the early judgments in Kohl and Decker, the impact of the free movement provisions on the 
healthcare sector has been analysed extensively. Most of this analysis has adopted a systemic 
perspective and has focussed on the effect of the application of free movement law on national 
healthcare systems. The article has shifted the perspective to the patient and to the quality of 
healthcare that patients are entitled to receive under national healthcare systems. The impact of 
free movement law on the standards that are applicable to medical treatment has been 
investigated through an analysis of the impact of Article 56 TFEU, the Cross-Border Healthcare 
Directive and European standardisation in the healthcare sector. The competence of the Member 
States to independently and autonomously determine the applicable standards for medical 
treatment has been restricted by the application of the free movement provisions. They have 
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forced Member States to engage in a comparative assessment of medical standards in the EU. As 
a result, they are obliged to open their eyes to what is going on in other Member States in terms 
of scientific evidence and medical standards. Although this obligation formally exists only in the 
context of cross-border healthcare, it also has an impact on the quality of healthcare that is 
provided to patients who are unable to travel to another Member State for medical treatment.  
Overall, the free movement provisions have increased the quality of medical treatments that are 
available to patients at the national level. There has not been a race to the bottom and free 
movement law has helped patients. This does not come as a surprise, because in all cases that 
were discussed a central role was played by the patient. The pro-active attitude of patients has 
forced national healthcare systems to improve their quality of healthcare. The potential of cross-
border healthcare has resulted in changes at the national level – not only to the benefit of 
travelling patients, but also to the benefit of less privileged patients who do not have the financial 
means to take the risk to travel to another Member State for medical treatment. As a result, 
patients have played and will continue to play a crucial role as campaigners for higher medical 
standards throughout the EU. The initiative for a European standard for Cleft Lip Surgery has 
shown that it is better to improve medical standards by challenging and exploring the full 
potential of national legislation than to aim for the introduction of uniform European standards. 
Such European standards would result in an average level of care and would remove incentives to 
improve quality of healthcare. Relying almost exclusively on negative integration means that 
differences in quality will remain, and that patients are encouraged to explore these differences. 
This process will be gradual, slow and dependent on private initiatives. Nevertheless, it has 
proved to be an effective strategy to improve medical standards throughout the EU.  
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